Chronic pulmonary heart disease is a common clinical condition with a high incidence of morbidity and mortality. Treatment of chronic pulmonary heart disease via conventional medicine aids in controlling infection, clearing respiratory tract airways, improving respiratory function, ameliorating hypoxia and carbon dioxide retention, as well as respiratory and cardiac failure. However, the results are not satisfactory. Treating chronic pulmonary heart disease using traditional Chinese Medicine (TCM) can enhance the body's immune function, reduce the frequency of acute exacerbations, improve the quality of life, as well as gradually restoring the lung and cardiac functions. TCM related clinical trials have been on the rise annually. However, the heterogeneity of these trial results pose as an obstacle for synthesizing clinical results in meta-analyses, thus reducing the value of clinical trials. There is also a risk of bias for selective reporting in clinical trials. Therefore, it is necessary and urgent to establish a Core outcome set (COS) on TCM for chronic pulmonary heart disease.
ContributorsPrincipal investigator:
Junhua Zhang, Mingyan Zhang, Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China
Other contributors:
Bohan Niu, Hui ZI CHUA, Ting Zhang, Kai Li, Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China
Disease Category: Heart & circulation
Disease Name: Chronic pulmonary heart disease
Age Range: 0 - 120
Sex: Either
Nature of Intervention: Complementary and alternative medicine (CAM) therapy, Traditional Chinese Medicine
- Clinical experts
- Conference participants
- Consumers (patients)
- Researchers
- COS for practice
- Consensus conference
- Delphi process
- Interview
- Systematic review
(1) Systematic literature review
(2) Qualitative semi-structured interviews
(3) Two rounds Delphi survey
(4) Consensus conference